1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

CHGCY
Chugai Pharmaceutical Co., Ltd.US flagOther OTC
23.15
USD
-0.67
- -
76.20BMarket Cap
Chugai Pharmaceutical Co., Ltd.
CHGCY
(Other OTC)

Recent

price

23.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
116.23
114.39
118.38
129.67
141
152.33
150.07
162.9
176.53
208.93
239.42
304.04
382.85
337.76
355.72
382.2
327.36
Revenue per Share
- -
- -
14.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
107.16
Basic EPS, GAAP
4.77
21.31
18.96
11.8
5.46
11.5
0.72
19.24
12.61
44.29
43.7
62.88
52.38
102.01
119.33
83.45
79.9
Free Cash Flow per Basic Share
6.66
7.17
6.67
7
7.5
8.67
9.67
9.16
10.66
17.16
27.82
30
42.01
39.99
40.49
90.97
39.62
Dividend per Share
122.69
126.32
112.08
152.79
160.29
171.6
177.1
190.27
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
136.91
150.82
160.07
172.53
179.33
187.43
191.39
204.87
223.44
252.85
290.89
354.61
425.25
488
572.38
598.9
522.58
Tangible Book Value per Share
3,265
3,265
3,265
3,267
3,270
3,275
3,277
3,279
3,284
3,284
3,287
3,288
3,290
3,290
3,291
3,291
3,313
Basic Weighted Avg Shares
379,509
373,516
386,552
423,652
461,109
498,839
491,780
534,199
579,787
686,184
786,946
999,758
1,259,726
1,111,367
1,170,611
1,257,941
1,084,569
Sales/Revenue/Turnover
28.69
16.71
19.32
18.59
16.45
17.4
15.63
18.52
21.44
30.69
38.28
42.2
42.34
39.52
46.3
47.6
44.85
Operating Margin (%)
17,982
15,900
15,330
14,490
14,880
15,567
16,369
16,334
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
46,052
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
355,040
Net Income, GAAP
35.16
36.51
35.55
32.57
31.63
28.56
26.97
24.21
23.36
24.21
27.99
27.75
29.51
26.67
28.68
27.4
27.37
Effective Tax Rate (%)
- -
- -
11.91
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
32.74
Profit Margin (%)
331,957
324,393
360,382
406,568
424,554
434,715
455,100
476,239
464,875
520,412
598,836
736,239
912,807
1,078,209
1,315,686
1,329,681
1,185,891
Working Capital
- -
170
213
195
185
604
510
207
82
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
449,394
498,989
529,161
573,204
597,756
627,271
646,497
692,897
756,528
853,985
980,003
1,188,017
1,424,387
1,625,580
1,901,499
2,025,732
1,751,691
Total Equity
15.44
8.2
9.13
9.42
8.64
9.87
8.65
10.95
12.81
19.1
22.38
26.31
26.88
20.2
21.03
21.07
20.8
Return on Invested Capital (%)
-0.29
-0.25
11.59
-0.23
-0.21
-0.22
-0.13
-0.12
-0.16
21.56
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
11.83
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,645
1,645
1,645
Market Capitalization
8,811,726
9,598,580
9,477,402

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,366,426
1,321,856
1,476,031
Cash, Cash Equivalents & STI
738,982
764,566
815,658
Accounts Receivable, Net
318,892
239,669
349,656
Inventories
273,480
276,682
265,704
Total Current Liabilities
288,217
238,981
290,140
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.58%
15.75%
6.53%
Free Cash Flow
279.89%
21.8%
-30.06%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
10.28%
10.81%
7.46%
Total Cash Common Dividend
31.54%
33.84%
124.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
236,949
315,911
- -
- -
1,170,611
2025
- -
- -
- -
- -
1,257,941
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22.61
33.31
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19.74
0.16
- -
- -
40.49
2025
- -
- -
- -
- -
90.97
2026
- -
- -
- -
- -
- -
Similar Companies
Santen Pharmaceutical Co., Ltd. (SNPHF)
AstraZeneca PLC (AZN)
Gland Pharma Limited (GLAND.NS)
Grifols, S.A. (GRFS)
Zoetis Inc. (0M3Q.L)
Pfizer Limited (PFIZER.BO)
Business
Chugai Pharmaceutical Co., Ltd., along with its affiliates, focuses on the discovery, development, production, and distribution of innovative prescription pharmaceuticals in Japan and across international markets. The company's diverse portfolio addresses critical therapeutic areas, including a robust presence in oncology, immunology, and neuroscience. Key marketed products encompass therapies like Actemra for rheumatoid arthritis, Hemlibra for hemophilia, Enspryng for neuromyelitis optica spectrum disorder, and a range of oncology treatments such as Tecentriq, Alecensa, Vabysmo, Lunsumio, and Polivy, alongside genomic profiling tools. Chugai actively invests in its research and development pipeline, pursuing new treatment modalities and leveraging advanced technologies like proprietary antibody engineering and AI-assisted drug discovery. Its development candidates span oncology, bone and joint conditions, autoimmune disorders, renal diseases, hematology, and ophthalmology, aiming to address significant unmet medical needs. Founded in 1925, the company maintains its headquarters in Tokyo, Japan. Chugai Pharmaceutical operates under a strategic alliance with the Roche Group, which holds a significant stake, enabling enhanced global reach and R&D capabilities while preserving Chugai's operational independence. This collaboration supports the continuous generation of novel drugs and services for patients worldwide. The company recently reported record high core revenues and profits in fiscal year 2024, with continued growth projected for 2025, driven by strong product performance and pipeline advancements, including new approvals for PiaSky and Alecensa, and progress in various clinical trials.

Company News

APIChat

  • seekingalpha.com

    Chugai Pharmaceutical Co., Ltd. (CHGCY) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript

  • zacks.com

    Chugai Pharmaceutical Co. (CHGCY) Upgraded to Buy: Here's Why

  • seekingalpha.com

    Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript

  • zacks.com

    Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

  • zacks.com

    Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why

  • zacks.com

    Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why

  • zacks.com

    Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know

  • zacks.com

    3 Stocks to Consider with Earnings Approaching